Sequana/Sloan-Kettering genomic research venture will focus on prostate, breast and colon cancer.
Executive Summary
SEQUANA/SLOAN-KETTERING VENTURE TO FOCUS ON PROSTATE, BREAST, COLON CANCER genomic research, Sequana announced Aug. 20. The focus of the research will be on "cancers caused by `somatic' mutations -- non-hereditary defects occurring in the genes of the body's cells that increase the risk for developing cancer," Sequana explained. Research will be aimed at identifying gene defects in the early stages of cancer and relating the gene defects to the subsequent course of treatment. The researchers will be looking to "provide tests that could predict how tumors will progress and respond to different therapies."